Discussions

PFIZER stock forum

Pfizer reported an 8% year-over-year drop in Q1 revenue, down to $13.7 billion—$370 million below expectations. However, adjusted earnings per share rose to $0.92, beating estimates by $0.24, thanks to strong cost management. COVID-related products continued to weigh on performance: Paxlovid sales plunged 76% year-over-year and missed forecasts, while Comirnaty jumped 62% and slightly exceeded projections. The company reaffirmed its 2025 revenue outlook of $61–$64 billion and adjusted EPS of $2.80–$3.00, though it cautioned that potential tariff effects haven't been factored in. Pfizer now targets $7.7 billion in cost reductions by 2027 through greater use of automation, AI, and streamlined processes.

After scrapping its obesity pill program over safety issues, Pfizer is looking at acquisitions to revive its cardiometabolic pipeline. The company faces long-term challenges including patent cliffs, regulatory threats from possible drug pricing changes, and waning investor confidence. Although it's cutting costs and investing in its R&D pipeline to steady the ship, Wall Street doubts Pfizer can replace the massive earnings it made during the COVID boom with new blockbuster drugs.

johnhs

: not sure why pfe does not perform... i am owner of pfe. i enjoy the dividend but don't get why there is a buyers strike.

Fool makes sense... pfe has to fill the pipeline. bought alt & vktx as well today.

johnhs

: possible to buy alt

fool.com/investing/2025/04/30/will-pfizer-will-acquire-altimmune-or-viking-thera/

KGI-Investments

After holding this security for over two years, we are downgrading this stock to sell from hold. After a series of poor decisions by management, they have proceeded to issue more new shares while slashing high impact projects like their weight loss drug, oncology pipeline, and research & development expense. We can no longer recommend this company with any level of certainty due to the very irresponsible use of capital, promises to shareholders that are getting broken quarter after quarter, and low after low. We don't see a reliable floor for this security anywhere at the moment. Very disappointed in the company and leadership. if they can even sustain their dividend remains to be seen.

HaezeL

this is going lower :(

m0402217

doesn't seem like it'll hold 25

KGI-Investments

Here is other real people’s opinions as well.

David Comments :
The hardest thing to learn in this business is knowing when NOT to sell, when not to “mess with” some thing that will only be worth a great deal more later. This stock, at this price, is still dirt cheap, selling at a 50% discount to the s&p AND at a superior dividend / long term earnings growth rate. The best is yet to come.

Johnathan writes :
Pfizer is being transparent with conservative estimates, the temporary costs of buying Seagen, upcoming expirations, and their robust pipeline of new drugs. True, earnings estimates are lower short-term. But estimated REVENUES for 2023 and 2024 are in the $54 to $58 billion range, about 30% HIGHER than their pre-COVID, 2020, $42 billion revenues. And, in the long run, revenues drive earnings! This stock is the big pharma “buy opportunity” of the decade.

Sammy writes : Bullish
PFE is slowly and steadily turning around. After a few rounds of shaking out, patience will be paid off sooner or later. I recently got onto this giant ship. Already got the January Dividend for the first time and will get April Dividend in a few weeks for the second time.
If the current quarter ER is good, this ship will sail north and not come back to $26 again, although I wish it could come back and give me another chance to load up more shares.

Lee writes : Bullish
While the bearish outlook on Pfizer’s stock may seem daunting, a closer examination reveals a company with solid fundamentals and a clear vision for the future. With its attractive dividend yield, cost-cutting measures, promising pipeline, and strategic focus, Pfizer appears well positioned to rebound and continue its legacy as a leading force in the pharmaceutical sector

Link to the posts for proof I’m not just stating these myself. : finance.yahoo.com/quote/PFE/community/

KGI-Investments

This company has been, and will continue to be our largest holding for the foreseeable future. The reasoning behind this is as follows.
• they have a secure, but rewardingly high dividend yield right now, due to the low share price they currently have.
• Their management team is extremely competent, and is executing a long term transformation of the company to pivot away from the COVID products and into other immunology and oncology pipelines.
• their weight loss drug has been effective in clinical trials, and is nearing full clearance for use across America. Tapping into this market will be very good for them as well. The once daily dose fixed the issues of higher side effects they saw at the twice a day dose, and showed to be just as effective as it. This is great news, as any progress in this area will generate billions.
• Pfizer has been one of the most active traded American healthcare companies on the market almost every day for the past several quarters. This indicates that there is buying interest still present, and that its price floor of $25.5 has held steady. (If it did drop below that, we would not hesitate to increase our weekly purchases of this equity. It only ever does for a very, very short time. )

And several more reasons I don’t have time to go over here. If anyone has any questions or wants to make any comments about this stock, feel free to message us directly on this platform. It has been, and will be, our largest holding for the foreseeable future. I am not trying to convince, persuade, or even advise here, simply stating the facts, and fairly disclosing that we are very satisfied owners of Pfizer stock, and explaining why we feel comfortable holding thousands of shares of Pfizer despite some turbulence.

HaezeL

This gets pumped every morning and then shot down

Jseng

is this dividend safe? They have a High dividend payout ratio